AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00302159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
Study NCT04477993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janus Kinase Inhibitor (ruxolitinib)
Description: 5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
Study NCT04477993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets P.O. b.i.d. for 14 days.
Study NCT01777490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helping Invested Families Improve Veterans Experiences - Control
Description: Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
Study NCT01777490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Invested Families Improve Veterans Experiences - HI FIVES
Description: In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
Study NCT04187716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject.
Study NCT04187716 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ferinject
Description: For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject.
Study NCT00265408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT00265408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study NCT02400203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT02400203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp foods
Study NCT02788318 — intervention group
Intervention type: OTHER
Intervention: Brain samples
Description: Collected in patients died
Study NCT02788318 — intervention group
Intervention type: OTHER
Intervention: Skin samples
Description: Collected in patients died
Study NCT01336205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily
Study NCT01336205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: As prescribed by the investigator
Study NCT00336817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: Myfortic 360mg or 720 mg BID for 90 days
Study NCT00336817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: CellCept 500mg or 1000mg BID for 90 days
Study NCT01846403 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative urine pregnancy test
Study NCT02813993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health educational video
Study NCT03757871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser stimulation
Description: an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
Study NCT03757871 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser stimulation
Description: an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
Study NCT03707847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg, BID, PO
Study NCT03707847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Capsule
Description: 50mg, QD, PO, d1-10，21days for one cycle
Study NCT03707847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Description: Auto-HSCT will be performed with patients who have achieved CR or VGPR.
Study NCT02561247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prismaflex HF20 CRRT Filter
Study NCT02561247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prismaflex® System 7.10 and 7.20
Study NCT00093977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa SF
Description: Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL
Study NCT02703896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug either PPIS or H2RA and prokinetics
Description: Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
Study NCT02703896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug either PPIS or H2RA and prokinetics
Description: Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
Study NCT02703896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug either PPIS or H2RA and prokinetics
Description: Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
Study NCT02703896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orogastric intubation
Description: OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
Study NCT02703896 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: orogastric intubation
Description: OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
Study NCT02703896 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: orogastric intubation
Description: OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
Study NCT04091815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of anaesthesia
Description: Two different types of anesthesia general vs combined (spinal and general)
Study NCT04091815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of anaesthesia
Description: Two different types of anesthesia general vs combined (spinal and general)
Study NCT05037890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Margarine
Description: Intake of margarine
Study NCT05037890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Margarine
Description: Intake of margarine
Study NCT04598295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-01
Description: synbiotic
Study NCT04598295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DS-01
Description: synbiotic
Study NCT01916421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Study NCT01318746 — intervention group
Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: blood withdrawal every 2 hours during 24 hours
Study NCT03990779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiographic examination before and after cardiopulmonary bypass
Study NCT02130700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally twice daily in 28-day cycles
Description: Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study NCT02130700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28-day cycles
Description: Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study NCT01927107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics mixture
Description: Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
Study NCT01692522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: visualized blind intubation
Study NCT01692522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: visualized blind intubation
Study NCT00456261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m2
Study NCT00456261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1500 mg/m2
Study NCT00456261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 10mg/kg bevacizumab 15mg/kg
Study NCT00456261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=5
Study NCT02094950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT03280745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
Study NCT03280745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Study NCT03471806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food reward at baseline
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
Study NCT03471806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food reward after treatment
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
Study NCT01465256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
Study NCT04394663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose oral omeprazole
Description: Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.
Study NCT04394663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV PPI
Description: Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
Study NCT00693615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine
Description: IM injection
Study NCT00693615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3
Description: IM injection
Study NCT00693615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
Description: IM injection
Study NCT00671047 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: SLE nature history observational
Study NCT03884309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Hydrolyzed Protein Infant Formula
Description: fed ad libitum
Study NCT04500678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
Study NCT00408187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.4 mg/kg po BID
Study NCT00408187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: ciclosporin 1.5 mg/kg po BID
Study NCT00408187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01461473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP)
Description: Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
Study NCT01461473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance (OA)
Description: Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
Study NCT00871364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VENLAFAXINE TABLETS 50 mg , single dose
Description: A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
Study NCT00871364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® Tablets equivalent to 50 mg venlafaxine
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
Study NCT04912414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Therapy (BFT)
Description: Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
Study NCT01556932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABH gel
Description: Given topically
Study NCT01556932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given topically
Study NCT03116009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Screening for diabetes with 1-hour GCT and HbA1
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
Study NCT03116009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Screening for diabetes with 1-hour GCT and HbA1
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
Study NCT01981811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Study NCT01981811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible Event Marker (IEM)
Study NCT01006590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg, oral tablet, once daily
Study NCT01006590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
Study NCT00057005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Day-8 through Day-6 according to institutional SOPs
Study NCT00057005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Day-5 400 μg/kg
Study NCT00057005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: day-7 through day-5 3000 mg/m2 q 12h
Study NCT00057005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day-7 through Day-6 45 mg/kg
Study NCT00057005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Days -7 and -6 45 mg/kg divided into 5 doses
Study NCT00057005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
Study NCT00487097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic acid, docosahexaenoic acid
Description: Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
Study NCT01742754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
Study NCT03492905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behaviour Therapy (iCBT)
Description: Guided self-help for 7 weeks. Contact with therapist 2 times per week.
Study NCT02598778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate (0.12%)
Description: 30 second oral rinse of 10mL of solution
Study NCT02598778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride (0.05%)
Description: 30 second oral rinse of 10mL of solution
Study NCT02598778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Paraffin wax chewing gum (sugar-free)
Description: Approximately two minutes of chew time